Abstract: A compound of the formula wherein the substituents are defined as in the specification which compounds are useful in the treatment of cancer.

Abstract: Compositions for treating cancer comprising an amount of a camptothecin with a 7-ring &bgr;-hydroxy lactone ring of the formula 1

Abstract: A compound of the formula wherein the substituents are defined as in the specification which compounds are useful in the treatment of cancer.

Abstract: A method of treating a cancer in warm-blooded animals by administration to the warm-blooded animals in need thereof a camptothecin analog a 7-ring member &bgr;-hydroxy lactone ring of the formula wherein the substituents are defined as in the specification.

Abstract: The invention concerns a product comprising at least mikanolide, dihydromikanolide or an analogue thereof combined with at least another anti-cancer agent for simultaneous, separate or prolonged therapeutic use in cancer treatment. In a preferred embodiment of the invention, the mikanolide, dihydromikanolide or one analogue thereof is combined with enzymatic inhibitors such as G heterotrimeric protein inhibitors or alkylating agents such as cis-platinum.

Abstract: A process for the preparation of a compound of the formula wherein the substituents are defined as set forth in the specification comprising reacting a compound of the formula with a 2-halo-3-quinoline-methanol of the formula to obtain a compound of the formula which is then cyclized to form the compound of Formula I.

Abstract: The invention concerns novel mikanolide derivatives, their preparation method and their therapeutic uses, in particular as anti-cancer and anti-viral agents. The compounds correspond to general formula (1) corresponding to general sub-formulae (I)1 and (I)2, wherein: R1 represents H, SR4 or NR4R5; R2 represents SR6 or NR6R7; R3 represents OH, O(CO)R14, OSiR15R16R17, O(CO)OR18 or O(CO)NHR18, each of the radicals R4, R6, R15, R16 and R17 representing independently (in particular) an alkyl radical, the radicals R5 and R7 representing (in particular) radicals selected independently among a hydrogen atom and an alkyl radical, and each of the radicals R14 and R18 representing independently (in particular) an alkyl or cycloalkyl radical, or one among aryl, heteroaryl, aralkyl or heteroalkyl radicals optionally substituted; provided that when the compounds correspond to the general sub-formula (I)2, then R1 does not represent a hydrogen atom.

Abstract: The invention relates to new tetracyclic analogues of camptothecin, their preparation processes, their use as medicaments and the pharmaceutical compositions containing them. Said analogues, which include in particular 3-hydroxy-3-(4-oxo-4,6-dihydroindolizino[1,2-b]quinoline-2-yl)pentanoic acid, have a powerful biological activity inhibiting topoisomerase I and/or topoisomerase II.

Abstract: A compound of the formula 1

Abstract: A process for the preparation of a compound of the formula 1

Abstract: The invention relates to new tetracyclic analogues of camptothecin, their preparation processes, their use as medicaments and the pharmaceutical compositions containing them. Said analogues, which include in particular 3-hydroxy-3-(4-oxo-4,6-dihydroindolizino [1,2-b] quinoline-2-yl)pentanoic acid, have a powerful biological activity inhibiting topoisomerase I and/or topoisomerase II.

Abstract: The compound of the formula wherein the substituents are defined as in the specification and its non-toxic, pharmaceutically acceptable salts which are useful for the treatment of viral infections, parasitic diseases and the treatment of cancer.

Abstract: A compound of the formula wherein the substituents are as defined in the specification and a method of inhibiting tumors.

Abstract: The invention relates to new tetracyclic analogues of camptothecin, their preparation processes, their use as medicaments and the pharmaceutical compositions containing them. Said analogues, which include in particular 3-hydroxy-3-(4-oxo-4,6-dihydroindolizino [1,2-b] quinoline-2-yl)pentanoic acid, have a powerful biological activity inhibiting topoisomerase I and/or topoisomerase II.

Abstract: A camptothecin analog characterized in that the hydroxy lactone of the camptothecin is a .beta.-hydroxy lactone or the corresponding .beta.-hydroxyacid, resulting from the opening of said lactone, or a derivative of said .beta.-hydroxyacid, or a Pharmaceutically acceptable salt thereof, is disclosed. In particular, compounds of formulae (I) and (II) are disclosed. Methods for preparing the compounds of formulae (I) and (II), pharmaceutical compositions containing said containing said compounds, and their use, particularly as topoisomerase inhibitors and antitumoral drugs, are also disclosed.